| Page 1208 | Kisaco Research
 

Yulin Lu

Yalibio

Yulin Lu

Yalibio

Yulin Lu

Yalibio
 

Jeff McKenna

Director
Novartis

Jeff McKenna

Director
Novartis

Jeff McKenna

Director
Novartis
 

Walker Graham

Jellatech

Walker Graham

Jellatech

Walker Graham

Jellatech
 

Nathaniel

Wilismilk

Nathaniel

Wilismilk

Nathaniel

Wilismilk
 

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis
 

Max Johansen

Novonutrients

Max Johansen

Novonutrients

Max Johansen

Novonutrients
 

C. Vivek Lal

Founder & CEO
ResBiotic

C. Vivek Lal

Founder & CEO
ResBiotic

C. Vivek Lal

Founder & CEO
ResBiotic
 

Karen Miller

Senior Scientist
BioTheryX

Initial introduction to molecular glues during tenure at Celgene from 2010-2015 where she was a key member on the IMiD “mechanism of action” discovery team. Work here directly contributed to the clinical development of pomalidomide and downstream mechanistic discovery of IMiDs including in-house identification of Ikaros, Aiolos, and GSPT1 as neosubstrates of various IMiD molecules.  Subsequently, left Celgene to obtain her PhD from The Scripps Research Institute under the tutelage of Dr.

Karen Miller

Senior Scientist
BioTheryX

Karen Miller

Senior Scientist
BioTheryX

Initial introduction to molecular glues during tenure at Celgene from 2010-2015 where she was a key member on the IMiD “mechanism of action” discovery team. Work here directly contributed to the clinical development of pomalidomide and downstream mechanistic discovery of IMiDs including in-house identification of Ikaros, Aiolos, and GSPT1 as neosubstrates of various IMiD molecules.  Subsequently, left Celgene to obtain her PhD from The Scripps Research Institute under the tutelage of Dr. Michael McHeyzer-Williams, focusing on adaptive immunity through germinal center formation and evolution. Following completion of her degree in 2021, she returned to the TPD space, moving to Biotheryx where she is currently the biology lead for both the BTX-1188 and Neosubstrate Discovery projects.

 

Katie Kam

CEO & Co- Founder
BioBQ

Katie Kam

CEO & Co- Founder
BioBQ

Katie Kam

CEO & Co- Founder
BioBQ